Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
The company needed a hit in its spine trial, and it claims to have got one.
While praising Novartis for kickstarting the CAR-T revolution, the chief exec of Tmunity has no doubt where cell therapy’s development engine really lies.
Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.